Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial DNA replication is the essential process by which bacteria duplicate their genetic material before cell division. It involves a highly coordinated series of steps—initiation, elongation, and termination—carried out by a multi-protein complex known as the replisome. Key components include: **Initiation:** Begins at a single origin of replication (*oriC*), where DnaA protein binds specific sequences ("DnaA boxes") causing local unwinding. Additional proteins such as DnaB helicase and DnaC loader are recruited to further unwind the helix[4][3]. **Elongation:** The main replicative enzyme is **DNA polymerase III**, which synthesizes new strands using RNA primers laid down by primase. Helicases continue unwinding the double helix while single-stranded binding proteins stabilize exposed templates. Topoisomerases like **DNA gyrase** relieve torsional strain ahead of the fork[1][6]. **Termination:** Replication ends when forks meet on the circular chromosome; specialized proteins resolve concatenated chromosomes. This process is rapid (~1000 nucleotides/second in *E. coli*) and highly accurate due to proofreading activities[1][5]. Many antibiotics exploit differences between bacterial and eukaryotic replication machinery—for example, quinolones inhibit bacterial topoisomerases but not their human counterparts. While "bacterial DNA replication" refers broadly to an essential cellular process rather than a single molecular entity or receptor, its core enzymatic components—such as **DNA gyrase**, **topoisomerases**, **primases**, and especially **DNA polymerase III**—are validated therapeutic targets for antibacterial drug development[1][5]. Therefore, this entry should ideally be split into its constituent protein targets for structured data purposes. > Note: "Bacterial DNA replication" describes a biological process involving multiple molecular targets rather than one discrete molecule or receptor; thus it does not fit standard conventions for canonical naming as used with individual drug targets like receptors or enzymes.[1][4][6]
Inhibition of topoisomerases to prevent relaxation of supercoiled DNA and block replication fork progression; Inhibition of primases or polymerases to halt chain elongation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial DNA replication.